What I think also bodes well for CHM is that our 2101 T-cell...

First 688 Last

Share
Profile

Follow
Shellbell

7,692 Posts.

3259

29/04/24

08:48

Post #: 73550343
Share
Originally posted by pinch2020: ↑

This bodes well for CHM 2101 safety profile.

https://www.arbelebio.com/2024/04/27/2024-04-27/

Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers
NEWS PROVIDED BY
Arbele
Apr 26, 2024, 9:00 AM ET
The second DMC review recommends the continuation of dose escalation in the clinical trial as per protocol.
The interim safety assessment was based on the review of safety data from 18 metastatic gastrointestinal cancer patients, including patients that have tolerated multiple doses of cabotamig.
The DMC review confirms the safety risk profile of cabotamig being consistent with published T-cell engagers.
SEATTLE,April 26, 2024/PRNewswire/ -- Arbele, a clinical-stage biotechnology company focused on the development of novel immunotherapies targeted for advanced gastrointestinal cancers, today announced the positive recommendation from the second meeting of the Data Monitoring Committee (DMC) to continue the A001 Phase I clinical trial evaluating cabotamig (ARB202) in patients with advanced gastrointestinal (GI) cancers without modification to the trial protocol. The DMC, composed of a group of independent experts, arrived at this recommendation after review of the interim safety data of patients enrolled in the A001 trial.
This safety assessment was based on the review of safety data from 18 patients, including patients that have been treated with multiple doses of cabotamig. This positive recommendation confirms tolerability profile of cabotamig is consistent with published safety data of T-cells engagers in other indications.
"We are greatly indebted to the courageous subjects who have participated in this early study of cabotamig that have allowed us better understand the safety profile while optimizing the dosing of this promising therapy" said DrDennis Wong, Chief Medical Officer at Arbele.

https://clinicaltrials.gov/study/NCT05411133?cond=GI%20Cancer&intr=CDH17%20%20CD3%20cabotamig%20&rank=1

This study is phase 1 only. The study started 30/5/2022 and is estimated to be completed 8/2025.

This why we are extremely lucky to have the management we have, experience around trial design and knowledge in the field is invaluable.

Our phase 1/2 study is estimated to start midway through this year and estimated to be completed 6/2026. We will be years ahead of this other trial if successful. First to market big carrot for big pharma.

Expand

What I think also bodes well for CHM is that our 2101 T-cell construct is already being proven up via our Chlorotoxin-binding product in the clinic treating GBM. Essentially, the differentiator between Arbele's Cabotamig (ARB202) and our CHM2101 is the number and type of intracellular targets.

According to our most recent preso, there are only three competitor therapies currently in development in clinical trials using CDH17 which is significant in itself... but the fact that our CAR construct is interchangeable with CLTX would make it highly attractive to Big Pharma, surely? And, that is exactly what JC highlights in recent interviews and presentations.

What you raise about Merck and Keytruda's upcoming patent expiry is a really great point. I dare say that your statement: "I dare say Merck are keeping a very close eye on how CHM 2101 progresses." is spot on! The reason I say that is: "ARBELE is a biotech company founded in 2016 by former senior executives from Johnson & Johnson, Roche, Sanofi, and Bristol-Myers Squibb." according to this blog:-

Thanks, pinch!
Last edited by Shellbell: 29/04/24

CHM Price at posting: 3.0¢ Sentiment: Buy Disclosure: Held
18 Upvote

2 Great analysis

Reply